

THE EFFECT OF FORMULATION
AND MANUFACTURING PROCESSES
ON THE CHARACTERISTICS OF
DIRECT COMPRESSION TABLETS

by

IAN MARTIN SANDERSON, B.Pharm.(Hons.),M.P.S.

Thesis submitted to
THE UNIVERSITY OF NOTTINGHAM
for the degree of
DOCTOR OF PHILOSOPHY

October, 1986.

Contents

	Page Number
Abstract.	vii
Acknowledgements.	ix
List of Figures and Plates.	x
List of Tables.	xv
 CHAPTER 1 Introduction.	 1
1.1 An Overview.	2
1.2 Tablet Manufacturing.	4
1.3 Tablet Strength.	9
1.4 Friability.	11
1.5 Porosity.	11
1.6 Weight Variation.	14
1.7 Liquid Penetration.	18
1.8 Disintegration.	21
1.9 Dissolution.	24
1.9.1 Dissolution from a Surface.	25
1.9.2 Dissolution of Powders.	28
1.9.3 Dissolution from a Tablet.	29
1.9.4 Dissolution Methods.	34
1.10 Statistical Methods in Formulation.	40
1.10.1 Optimisation Methods.	40
1.11 Aims and Objectives.	47
 CHAPTER 2 Materials, Apparatus, Methods and Preliminary Investigations.	 48
2.1 Introduction.	49
2.2 Material Preparation.	49
2.3 Paracetamol Particle Sizing Methods.	
2.3.1 Initial Methods.	56
2.3.2 Microscopic Methods.	58
2.3.3 Fisher Subsieve Sizing.	60
2.3.4 Laser Diffraction.	61

	Page Number
2.4 Preliminary formulation work.	61
2.5 Tablet Manufacture.	63
2.5.1 Mixing.	63
2.5.2 Tableting.	66
2.5.3 Tablet Tests.	69
2.6 Dissolution Tests.	74
2.6.1 Dissolution Apparatus.	74
2.6.2 Calibration of the Kontron dissolution system.	75
2.6.3 Dissolution Methods.	82
2.7 The determination of suitable mixing times and disintegrant concentrations.	85
2.8 Friability and Liquid Penetration tests.	88
2.9 Conclusions from the preliminary formulations.	91
 CHAPTER 3 Results.	93
3.1 Introduction.	94
3.2 The Particle Size of Paracetamol.	94
3.3 The Particle Size of Aspirin.	98
3.4 Tablet manufacture and testing.	99
 CHAPTER 4 The Statistical Analysis of the Results Derived from Paracetamol Tablets.	143
4.1 Introduction.	144
4.2 Statistical Analysis of the Treatments Relating to the Tablet Weight Variation of Paracetamol Tablets.	147
4.3 Statistical Analysis of the Treatments Relating to the Porosity of Paracetamol Tablets.	152

4.4	Statistical Analysis of the Treatments Relating to the Tensile Fracture Stress of Paracetamol Tablets.	159
4.5	Statistical Analysis of the Treatments Relating to the Friability of Paracetamol Tablets.	166
4.6	Statistical Analysis of the Treatments Relating to the Uptake of Liquid by Paracetamol Tablets.	168
4.7	Statistical Analysis of the Treatments Relating to the Dissolution of Paracetamol from Tablets.	178
4.8	The Relationship Between Tensile Fracture Stress and T90% in Paracetamol Tablets.	188
4.9	A Summary of the effects of the treatments on the characteristics of paracetamol tablets.	191
4.9.1	The Effect of a Longer Mixing Time	191
4.9.2	The Effect of Increasing the Drug Particle Size.	192
4.9.3	The Effect of Increasing the Starch Concentration.	196
4.9.4	The Effect of Increasing the Compaction Pressure.	198

CHAPTER 5	The Statistical Analysis of the Results Derived from Aspirin Tablets.	202
5.1	Introduction.	203
5.2	The Analysis of Variance based on the Coefficient of Weight Variation of Aspirin Tablets.	204
5.3	The Analysis of Variance based on the Porosity of Aspirin Tablets.	206
5.4	The Analysis of Variance based on the Tensile Fracture Stress of Aspirin Tablets.	209
5.5	The Analysis of Variance based on the Friability of Aspirin Tablets.	215
5.6	The Analysis of Variance based on the Liquid Uptake into Aspirin Tablets.	220
5.7	Statistical Analysis of the Treatments Relating to the Dissolution of Aspirin Tablets.	227
5.8	A Summary of the effects of the Treatments on Aspirin Tablets.	239
5.8.1	The effect of altering the mixing time	239
5.8.2	The effect of changing the starch concentration.	240
5.8.3	The effect of changing the compaction pressure.	241

	Page Number
CHAPTER 6 A Comparison of the Characteristics of Aspirin and Paracetamol Tablets.	243
6.1 Introduction.	244
6.2 Tablet Weight Variation and Porosity.	247
6.3 Tablet Strength.	250
6.4 Liquid Penetration.	253
6.5 The Dissolution Rate.	255
6.6 Conclusions.	258
6.7 Further Work.	261
6.7.1 General Considerations.	261
6.7.2 Detailed Considerations.	262
Bibliography.	267
Appendix.	281

ABSTRACT

Two model direct compression tablet formulations have been examined by means of factorially designed experiments. The formulations were based on a direct compression vehicle (Avicel) containing 25%w/w of either paracetamol or aspirin. A disintegrant (maize starch), a lubricant (magnesium stearate) and a glidant (Aerosil) were also included. The influence of changes in mixing time and compaction pressure were used to represent changes in the manufacturing process. Alterations to the starch concentration and the drug particle size were chosen to reflect formulation changes. The coefficient of weight variation, porosity, tensile fracture stress, friability, the time for 50% liquid saturation of the tablets, and 90% of drug dissolution were used to monitor the effects of the changes.

The lubricant distribution, as determined by the mixing time, was found to control the tablet strength to a greater extent than the other factors. With the paracetamol formulations, where the particle size was similar to the bulk of the excipients, the particle size also had an appreciable effect on the tablet strength. The compaction pressure was the least effective factor.

A novel method of measuring liquid uptake into tablets based on gamma scintigraphy showed that the penetration into aspirin tablets was largely determined by the tablet strength. The uptake into paracetamol tablets was controlled by the drug particle size and the mixing time.

ie. strength
see later

Increasing the starch concentration increased the dissolution rate, but this has been postulated to be due to an interaction of the starch with the drug surface rather than any disintegrant action. The drug particle size had a significant effect on the dissolution of the paracetamol tablets where the larger size dissolved more rapidly. There was little effect on the aspirin tablets where the drug size was greater than that of the other excipients.

ACKNOWLEDGEMENTS.

This work would not have been possible without the support and encouragement of Dr. J. W. Kennerley and Dr. G. D. Parr, to whom I would like to express my thanks.

Any experimental work requires the maintenance of equipment, the procurement of apparatus and space to carry out those experiments. To this end I would also like to express my thanks to the technical staff of the Pharmacy Department at Nottingham University, not forgetting those concerned with the administration.

A large proportion of this project has been concerned with the statistical analysis of results and I would like to thank Mr. P. Riley for his invaluable advice on experimental design and analysis. Thanks also to the other members of staff in Cripps Computing Centre at Nottingham University.

The finance provided by the S.E.R.C. in conjunction with E. R. Squibb and Sons Ltd. made the project feasible.

Finally I would like to thank Ann for smoothing out the rough patches.

List of Figures and Plates

Figure Number		Page Number
1.1	The Processes Involved in the Delivery of a Drug to its Site of Biological Activity.	3
1.2	Two commonly available designs of drum used in friability tests.	12
1.3	The processes involved in the conversion of a drug contained in a tablet to a solution available for absorption.	24
1.4	Diagrammatic representation of three models describing the dissolution of a solid from a surface.	27
1.5	The effect of the compaction pressure on the dissolution of a drug from a tablet.	35
1.6	The common designs of apparatus for in-vitro dissolution testing.	37
1.7	The Test Conditions for Evolutionary Operation.	43
2.1	The principal components of an Alpine Zig-Zag Classifier.	53
2.2	Photomicrograph of the undersize cut of paracetamol obtained from a Zig-zag classifier.	59
2.3	Photomicrograph of the oversize cut of paracetamol obtained from a Zig-zag classifier.	59
2.4	Diagrammatic cross sections of the mixers used during formulation development.	64
2.5	Detail of the Modified Hobart mixer used in the production of the experimental tablets.	65
2.6	Detail of the upper punch and load washer assembly.	67

Figure Number		Page Number
2.7	Flow diagram of the Fortran program used to process tabletting data.	72
2.8	Schematic diagram of the Kontron dissolution apparatus.	76
2.9	Beer calibration plot for paracetamol in 0.1M HCl at 37°C and 270nm.	78
2.10	The change in absorbance with time at different wavelengths due to acid hydrolysis of aspirin.	80
2.11	Beer calibration plot for aspirin in 0.1M HCl at 37°C and 278nm	81
2.12	Flow diagram of the Fortran computer program used to process dissolution data.	84
2.13	The relationship between the tensile fracture stress and the mixing time in preformulation studies.	86
2.14	Schematic diagram of the equipment used in liquid uptake studies.	90
3.1	The particle size distribution of two size fractions of paracetamol based on microscopic and laser scatter determinations.	97
Plate 3.1	An example of the visual record obtained during the liquid uptake studies.	109

Figure Number		Page Number
3.2	The mean dissolution profiles from paracetamol tablets batches 1 to 3.	111
3.3	The mean dissolution profiles from paracetamol tablets batches 4 to 6.	112
3.4	The mean dissolution profiles from paracetamol tablets batches 7 to 9.	113
3.5	The mean dissolution profiles from paracetamol tablets batches 10 to 12.	114
3.6	The mean dissolution profiles from paracetamol tablets batches 13 to 15.	115
3.7	The mean dissolution profiles from paracetamol tablets batches 16 to 18.	116
3.8	The mean dissolution profiles from paracetamol tablets batches 19 to 21.	117
3.9	The mean dissolution profiles from paracetamol tablets batches 22 to 24.	118
3.10	The mean dissolution profiles from aspirin tablets batches 1 to 3.	119
3.11	The mean dissolution profiles from aspirin tablets batches 4 to 6.	120
3.12	The mean dissolution profiles from aspirin tablets batches 7 to 9.	121
3.13	The mean dissolution profiles from aspirin tablets batches 10 to 12.	122
3.14	The mean dissolution profiles from aspirin tablets batches 13 to 15.	123
3.15	The mean dissolution profiles from aspirin tablets batches 16 to 18.	124
3.16	The mean dissolution profiles from aspirin tablets batches 19 to 21.	125

Figure Number		Page Number
3.17	The mean dissolution profiles from aspirin tablets batches 22 to 24.	126
3.18	The liquid uptake profiles from paracetamol tablets batches 1 to 3.	127
3.19	The liquid uptake profiles from paracetamol tablets batches 4 to 6.	128
3.20	The liquid uptake profiles from paracetamol tablets batches 7 to 9.	129
3.21	The liquid uptake profiles from paracetamol tablets batches 10 to 12.	130
3.22	The liquid uptake profiles from paracetamol tablets batches 13 to 15.	131
3.23	The liquid uptake profiles from paracetamol tablets batches 16 to 18.	132
3.24	The liquid uptake profiles from paracetamol tablets batches 19 to 21.	133
3.25	The liquid uptake profiles from paracetamol tablets batches 22 to 24.	134
3.26	The liquid uptake profiles from aspirin tablets batches 1 to 3.	135
3.27	The liquid uptake profiles from aspirin tablets batches 4 to 6.	136
3.28	The liquid uptake profiles from aspirin tablets batches 7 to 9.	137
3.29	The liquid uptake profiles from aspirin tablets batches 10 to 12.	138
3.30	The liquid uptake profiles from aspirin tablets batches 13 to 15.	139
3.31	The liquid uptake profiles from aspirin tablets batches 16 to 18.	140

Figure Number		Page Number
3.32	The liquid uptake profiles from aspirin tablets batches 19 to 21.	141
3.33	The liquid uptake profiles from aspirin tablets batches 22 to 24.	142
4.1	The influence of hydrophobic inclusions on the penetration of liquid into a hydrophilic tablet matrix.	173
4.2	Scatter diagram of the mean T90% for each batch of paracetamol tablets and the associated mean tensile fracture stress.	190
5.1	Scatter diagram of the mean liquid uptake (M50%) and the mean tensile fracture stress for each batch of aspirin tablets.	224
6.1	The relationship between the mean tensile fracture stress and the reciprocal of the percentage friability for aspirin and paracetamol tablets.	251

List of Tables

Table Number		Page Number
1.1	A Comparison of the Methods of Preparing Drugs for Tabletting.	6
1.2	General Characteristics of Common Direct Compression Excipients.	8
1.3	Powder Measurements. Factors relating to powder flow.	16
1.4	The adhesion tension of various materials.	20
1.5	Proposed mechanisms for the action of Disintegrants.	22
1.6	Dissolution models.	30
1.7	The change in particle surface with size reduction.	32
1.8	Some examples of factorial design experiments.	46
2.1	Apparatus and Suppliers.	50
2.2	Materials and Suppliers.	52
2.3	The Apparent Particle Densities of the powders used.	55
2.4	Calibration of the Kontron Dissolution system with Paracetamol at 270nm.	77
2.5	The formulation used in mixing experiments.	85
2.6	Formulations used for disintegration tests.	87
2.7	The change in disintegration time with starch concentration.	88
3.1	The increase in surface-volume diameter of two size fractions of paracetamol with decreasing porosity on a Fisher sub-sieve sizer.	95

Table Number		Page Number
3.2	Mean surface-volume diameters determined by Fisher sub-sieve sizer at a porosity of 0.6.	95
3.3	The geometric mean diameter and standard deviation of two size fractions of paracetamol powder determined by different methods.	96
3.4	The Manufacturing Parameters Used in the Production of Batches of Paracetamol and Aspirin Tablets.	100
3.5	The experimental formulations used for the manufacture of aspirin and paracetamol tablets.	101
3.6	Assay figures for paracetamol tablets and target weight for mixes.	102
3.7	A Summary of the Experimental Results Relating to Paracetamol Tablets.	103
3.8	A Summary of the Experimental Results Relating to Aspirin Tablets.	104
3.9	The linear regression analysis of the relationship between tensile fracture stress and compaction pressure for paracetamol tablets.	106
3.10	The linear regression analysis of the relationship between tensile fracture stress and compaction pressure for paracetamol tablets.	107

Table Number		Page Number
4.1	The terms used in the Analysis of Variance (ANOVA) tables.	145
4.2	ANOVA table based on the coefficient of weight variation of paracetamol tablets.	148
4.2a	The mean coefficient of tablet weight variation attributable to the drug particle size.	149
4.2b	The mean coefficient of tablet weight variation attributable to the mixing time.	149
4.2c	The mean coefficient of tablet weight variation attributable to the interaction between the mixing time and the drug particle size.	149
4.3	ANOVA table based on the Porosity of paracetamol tablets.	153
4.3a	The mean tablet porosity attributable to the compaction pressure.	154
4.3b	The mean tablet porosity attributable to the starch concentration.	154
4.3c	The mean tablet porosity attributable to the drug particle size.	154
4.3d	The mean tablet porosity attributable to the mixing time.	155
4.3e	The mean tablet porosity attributable to the interaction between mixing time and the drug particle size.	155
4.4	ANOVA table based on the tensile fracture stress of paracetamol tablets.	160
4.4a	The mean tensile fracture stress attributable to the mixing time.	161

Table Number		Page Number
4.4b	The mean tensile fracture stress attributable to the drug particle size.	161
4.4c	The mean tensile fracture stress attributable to the starch concentration.	161
4.4d	The mean tensile fracture stress attributable to the compaction pressure.	162
4.4e	The mean tensile fracture stress attributable to the interaction between the drug particle size, mixing time and compaction pressure.	162
4.5	ANOVA table based on the Friability of paracetamol tablets.	167
4.6	ANOVA table based on the liquid uptake into paracetamol tablets.	170
4.6a	The mean liquid uptake attributable to the mixing time.	171
4.6b	The mean liquid uptake attributable to the drug particle size.	171
4.6c	The mean liquid uptake attributable to the compaction pressure.	171
4.6d	The mean liquid uptake attributable to the interaction between mixing time and drug particle size.	172
4.6e	The mean liquid uptake attributable to the interaction between mixing time, drug particle size and compaction pressure.	172
4.7	ANOVA table based on the time for 90% of the drug to dissolve from paracetamol tablets.	179

Table Number		Page Number
4.7a	The mean T90% attributable to the starch concentration.	180
4.7b	The mean T90% attributable to the drug particle size.	180
4.7c	The mean T90% attributable to the interaction between the drug particle size and starch concentration.	181
4.7d	The mean T90% attributable to the interaction between starch concentration, mixing time and drug particle size.	181
4.8	ANOVA table based on the time for 50% of the drug to dissolve from paracetamol tablets.	182
4.9	ANOVA table based on the time for 60% of the drug to dissolve from paracetamol tablets.	183
4.10	The Theoretical Ratio of Surface Areas of Paracetamol and Starch.	187
5.1	ANOVA table based on the coefficient of weight variation of aspirin tablets.	205
5.2	ANOVA table based on the porosity of aspirin tablets.	207
5.2a	The mean tablet porosity attributable to the compaction pressure.	208
5.2b	The mean tablet porosity attributable to the mixing time.	208
5.3	ANOVA table based on the tensile fracture stress of aspirin tablets.	210
5.3a	The mean tensile fracture stress attributable to the mixing time.	211

Table Number		Page Number
5.3b	The mean tensile fracture stress attributable to the starch concentration.	211
5.3c	The mean tensile fracture stress attributable to the compaction pressure.	212
5.3d	The mean tensile fracture stress attributable to the interaction between the starch concentration and the mixing time.	212
5.4	ANOVA table based on the friability of aspirin tablets.	216
5.4a	The mean friability attributable to the mixing time.	217
5.4b	The mean friability attributable to the starch concentration.	217
5.4c	The mean friability attributable to the compaction pressure.	217
5.4d	The mean friability attributable to the interaction between mixing time and starch concentration.	218
5.4e	The mean friability attributable to the interaction between mixing time and compaction pressure.	218
5.5	ANOVA table based on the liquid uptake into aspirin tablets.	221
5.5a	The mean liquid uptake attributable to the mixing time.	222
5.5b	The mean liquid uptake attributable to the starch concentration.	222

Table Number		Page Number
5.5c	The mean liquid uptake attributable to the interaction between mixing time and starch concentration.	222
5.5d	The mean liquid uptake attributable to the compaction pressure.	223
5.5e	The mean liquid uptake attributable to the interaction between starch concentration, mixing time and compaction pressure.	223
5.6	ANOVA table based on the time for 90% of the drug to dissolve from aspirin tablets.	228
5.6a	The mean T90% attributable to the starch concentration.	229
5.6b	The mean T90% attributable to the mixing time.	229
5.6c	The mean T90% attributable to the compaction pressure.	229
5.6d	The mean T90% attributable to the interaction between mixing time and starch concentration.	230
5.6e	The mean T90% attributable to the interaction between the starch concentration and compaction pressure.	230
5.6f	The mean T90% attributable to the interaction between mixing time and compaction pressure.	230

Table Number		Page Number
5.6g	The mean T90% attributable to the interaction between starch concentration, mixing time and compaction pressure.	231
5.7	ANOVA table based on the time for 50% of the drug to dissolve from aspirin tablets.	232
5.8	ANOVA table based on the time for 60% of the drug to dissolve from aspirin tablets.	233
6.1	A summary of the effect of an increase in a treatment on the tablet parameters.	245
6.2	The properties of aspirin and paracetamol.	246
A.1	Measurements derived from the manufacture of paracetamol tablets: batch 1.	A1
A.2	Measurements derived from the manufacture of paracetamol tablets: batch 2.	A1
A.3	Measurements derived from the manufacture of paracetamol tablets: batch 3.	A2
A.4	Measurements derived from the manufacture of paracetamol tablets: batch 4.	A2
A.5	Measurements derived from the manufacture of paracetamol tablets: batch 5.	A3
A.6	Measurements derived from the manufacture of paracetamol tablets: batch 6.	A3
A.7	Measurements derived from the manufacture of paracetamol tablets: batch 7.	A4
A.8	Measurements derived from the manufacture of paracetamol tablets: batch 8.	A4

A.9	Measurements derived from the manufacture of paracetamol tablets: batch 9.	A5
A.10	Measurements derived from the manufacture of paracetamol tablets: batch 10.	A5
A.11	Measurements derived from the manufacture of paracetamol tablets: batch 11.	A6
A.12	Measurements derived from the manufacture of paracetamol tablets: batch 12.	A6
A.13	Measurements derived from the manufacture of paracetamol tablets: batch 13.	A7
A.14	Measurements derived from the manufacture of paracetamol tablets: batch 14.	A7
A.15	Measurements derived from the manufacture of paracetamol tablets: batch 15.	A8
A.16	Measurements derived from the manufacture of paracetamol tablets: batch 16.	A8
A.17	Measurements derived from the manufacture of paracetamol tablets: batch 17.	A9
A.18	Measurements derived from the manufacture of paracetamol tablets: batch 18.	A9
A.19	Measurements derived from the manufacture of paracetamol tablets: batch 19.	A10
A.20	Measurements derived from the manufacture of paracetamol tablets: batch 20.	A10
A.21	Measurements derived from the manufacture of paracetamol tablets: batch 21.	A11
A.22	Measurements derived from the manufacture of paracetamol tablets: batch 22.	A11
A.23	Measurements derived from the manufacture of paracetamol tablets: batch 23.	A12

Table Number		Page Number
A.24	Measurements derived from the manufacture of paracetamol tablets: batch 24.	A12
A.25	Measurements derived from the manufacture of aspirin tablets: batch 1.	A13
A.26	Measurements derived from the manufacture of aspirin tablets: batch 2.	A13
A.27	Measurements derived from the manufacture of aspirin tablets: batch 3.	A14
A.28	Measurements derived from the manufacture of aspirin tablets: batch 4.	A14
A.29	Measurements derived from the manufacture of aspirin tablets: batch 5.	A15
A.30	Measurements derived from the manufacture of aspirin tablets: batch 6.	A15
A.31	Measurements derived from the manufacture of aspirin tablets: batch 7.	A16
A.32	Measurements derived from the manufacture of aspirin tablets: batch 8.	A16
A.33	Measurements derived from the manufacture of aspirin tablets: batch 9.	A17
A.34	Measurements derived from the manufacture of aspirin tablets: batch 10.	A17
A.35	Measurements derived from the manufacture of aspirin tablets: batch 11.	A18
A.36	Measurements derived from the manufacture of aspirin tablets: batch 12.	A18
A.37	Measurements derived from the manufacture of aspirin tablets: batch 13.	A19
A.38	Measurements derived from the manufacture of aspirin tablets: batch 14.	A19

Table Number		Page Number
A.39	Measurements derived from the manufacture of aspirin tablets: batch 15.	A20
A.40	Measurements derived from the manufacture of aspirin tablets: batch 16.	A20
A.41	Measurements derived from the manufacture of aspirin tablets: batch 17.	A21
A.42	Measurements derived from the manufacture of aspirin tablets: batch 18.	A21
A.43	Measurements derived from the manufacture of aspirin tablets: batch 19.	A22
A.44	Measurements derived from the manufacture of aspirin tablets: batch 20.	A22
A.45	Measurements derived from the manufacture of aspirin tablets: batch 21.	A23
A.46	Measurements derived from the manufacture of aspirin tablets: batch 22.	A23
A.47	Measurements derived from the manufacture of aspirin tablets: batch 23.	A24
A.48	Measurements derived from the manufacture of aspirin tablets: batch 24.	A24